Urol. praxi. 2024;25(3):156-159 | DOI: 10.36290/uro.2024.061

Dyspareunia

MUDr. Marek Broul, Ph.D., MBA, FECSM1, 2, 3, MUDr. Petra Kučerová1, 4, MUDr. Kamila Žižková1, 5, Mgr. Aneta Hujová3
1 Sexuologické oddělení, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z.
2 Urologické oddělení, Krajská zdravotní, a. s., Nemocnice Litoměřice, o. z.
3 Fakulta zdravotnických studií Univerzity J. E. Purkyně v Ústí nad Labem
4 Klinika urologie a robotické chirurgie Fakulty zdravotnických studií Univerzity J. E. Purkyně v Ústí nad Labem a Krajské zdravotní, a. s. - Masarykovy nemocnice v Ústí nad Labem, o. z.
5 Gynekologické oddělení, Krajská zdravotní, a. s., Nemocnice Chomutov, o. z.

Dyspareunia is defined as painful sexual intercourse. It can have a significant impact on partner relationships and the overall quality of life of affected women. This article reviews the current knowledge regarding the definition, prevalence, diagnosis and treatment of dyspareunia. It summarizes key information on current knowledge about dyspareunia and provides an essential foundation for clinical practice in sexual health.

Keywords: dyspareunia, pain during sexual intercourse, lichen planus, lichen simplex, lichen sclerosus, endometriosis, sexual abuse, vulvitis, vulvovaginitis.

Accepted: October 1, 2024; Published: November 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Broul M, Kučerová P, Žižková K, Hujová A. Dyspareunia. Urol. praxi. 2024;25(3):156-159. doi: 10.36290/uro.2024.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 14.11.2025

    References

    1. Female Sexual Dysfunction - DynaMed. Accessed January 27, 2024. https://www.dynamed.com/condition/female-sexual-dysfunction#GUID-5FB46BAF-FDCB-462F-8D96-F0E422203CBD.
    2. Glatt AE, Zinner SH, McCormack WM. The prevalence of dys­pareunia. Obstet Gynecol. 1990;75(3 Pt 1):433-436.
    3. Practice Bulletin No. 119: Female Sexual Dysfunc­tion. Obstetrics & Gynecology. 2011;117(4):996. doi:10.1097/AOG.0b013e31821921ce. Go to original source... Go to PubMed...
    4. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762-774. doi:10.1056/NEJMoa067423 Go to original source... Go to PubMed...
    5. Latthe P, Latthe M, Say L, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health. 2006;6(1):177. doi:10.1186/1471-2458-6-177. Go to original source... Go to PubMed...
    6. Moshesh M, Olshan AF, Saldana T, et al. Examining the relationship between uterine fibroids and dyspareunia among premenopausal women in the United States. J Sex Med. 2014;11(3):800-808. doi:10.1111/jsm.12425. Go to original source... Go to PubMed...
    7. Jozifkova E. Consensual sadomasochistic sex (BDSM): the roots, the risks, and the distinctions between BDSM and violence. Curr Psychiatry Rep. 2013;15(9):392. doi:10.1007/s11920-013-0392-1. Go to original source... Go to PubMed...
    8. Yong PJ, Sadownik L, Brotto LA. Concurrent deep-superficial dyspareunia: prevalence, associations, and outcomes in a multidisciplinary vulvodynia program. J Sex Med. 2015;12(1):219-227. doi:10.1111/jsm.12729. Go to original source... Go to PubMed...
    9. Pazmany E, Bergeron S, Van Oudenhove L, et al. Body ima­ge and genital self-image in pre-menopausal women with dyspareunia. Arch Sex Behav. 2013;42(6):999-1010. doi:10.1007/s10508-013-0102-4. Go to original source... Go to PubMed...
    10. Fait T. Menopauzální genitourinární syndrom: těžký komunikační problém, snadná léčba. Časopis lékařů českých. 2019;158(3-4):101-106.
    11. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. American Journal of Obstetrics and Gynecology. 1989;160(1):176-181. doi:10.1016/0002-9378(89)90114-2. Go to original source... Go to PubMed...
    12. Ulmsten U, Ekman G, Giertz G, et al. Different biochemical composition of connective tissue in continent and stress incontinent women. Acta Obstetricia et Gynecologica Scandinavica. 1987;66(5):455-457. doi:10.3109/00016348709022054. Go to original source... Go to PubMed...
    13. The Effects of Estrogens and Gestagens on the Urethral Pressure Profile in Urinary Continent and Stress Incontinent Women: Acta Obstetricia et Gynecologica Scandinavica. 2024;59:3. https://www.tandfonline.com/doi/abs/10.3109/00016348009155409.
    14. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric. 2012;15(3):267-274. doi:10.3109/13697137.2012.657589. Go to original source... Go to PubMed...
    15. Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226-232. doi:10.3109/13697137.2014.954996. Go to original source... Go to PubMed...
    16. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256. doi:10.1097/GME.0000000000000571. Go to original source... Go to PubMed...
    17. FDA approves Intrarosa for postmenopausal women experiencing pain during sex. FDA. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-intrarosa-postmenopausal-women-experiencing-pain-during-sex.
    18. Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. Am Fam Physician. 2014;90(7):465-470.
    19. Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for "vaginal rejuvenation." FDA. Published March 24, 2020. Accessed January 27, 2024. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.